With no efficacy data available, is the Bharat Biotech vaccine against the coronavirus safe and effective? The Serum Institute of India vaccine will be the main drug, AIIMS Director Dr Randeep Guleria told NDTV, adding that the Bharat Biotech vaccine will only be used as a backup. | NDTV
22:13
FacebookNDTV
With no efficacy data available, is the Bharat Biotech vaccine against the coronavirus safe and effective? The Serum Institute of India vaccine will be the main drug, AIIMS
NDTV. . With no efficacy data available, is the Bharat Biotech vaccine against the coronavirus safe and effective? The Serum Institute of India vaccine will be the main drug, AIIMS Director Dr Randeep Guleria told NDTV, adding that the Bharat Biotech vaccine will only be used as a backup.
50.3K viewsJan 2, 2021
Bharat Immunologicals and Biologicals Corporation Bharat Immunologicals Products
ఈ భీం మనని కాపాడతాడా
ఈ భీం మనని కాపాడతాడా
teluguone.com
Dec 31, 2016
NCRTC announces winners of Namo Bharat short film contest
NCRTC announces winners of Namo Bharat short film contest
theprint.in
9 months ago
Bharat Petroleum Corp Q3 net profit 75.45 bln rupees
Bharat Petroleum Corp Q3 net profit 75.45 bln rupees
marketscreener.com
4 months ago
Top videos
‘Covaxin has 81% efficacy’: Bharat Biotech phase 3 trial results
2:31
‘Covaxin has 81% efficacy’: Bharat Biotech phase 3 trial results
Hindustan TimesMohammad Shuaib
Mar 3, 2021
Bharat Biotech launches lowest dose rotavirus vaccine
Bharat Biotech launches lowest dose rotavirus vaccine
zeebiz.com
Dec 3, 2019
Bharat Biotech To Be Reportedly Valued At $600 Million As Top PE Firms Queue Up To Buy Stake
Bharat Biotech To Be Reportedly Valued At $600 Million As Top PE Firms Queue Up To Buy Stake
marketscreener.com
Feb 7, 2016
Bharat Immunologicals and Biologicals Corporation Bharat Immunologicals Vaccine
WHO nod for Bharat Biotech's Covaxin for EUL expected by October
2:52
WHO nod for Bharat Biotech's Covaxin for EUL expected by October
India TodayIndia Today Television
Sep 30, 2021
Polio vaccine maker BIBCOL to manufacture 2 crore doses of Covaxin at UP's Bulandshahr plant every month
Polio vaccine maker BIBCOL to manufacture 2 crore doses of Covaxin at UP's Bulandshahr plant every month
INDIA TV
May 12, 2021
Bharat Biotech Says Phase 3 Results Public By July
1:57
Bharat Biotech Says Phase 3 Results Public By July
NDTVVishnu Som
Jun 9, 2021
‘Covaxin has 81% efficacy’: Bharat Biotech phase 3 trial results
2:31
‘Covaxin has 81% efficacy’: Bharat Biotech phase 3 trial results
Mar 3, 2021
Hindustan TimesMohammad Shuaib
Bharat Biotech launches lowest dose rotavirus vaccine
Bharat Biotech launches lowest dose rotavirus vaccine
Dec 3, 2019
zeebiz.com
Bharat Biotech To Be Reportedly Valued At $600 Million As Top PE Firms Queue Up To Buy Stake
Bharat Biotech To Be Reportedly Valued At $600 Million As Top PE Firms Queue Up To Buy Stake
Feb 7, 2016
marketscreener.com
COVID-19: Bharat Biotech confirms adverse event during vaccine trial
COVID-19: Bharat Biotech confirms adverse event during vaccine trial
Nov 21, 2020
india.com
Bharat Biotech announces price of nasal vaccine - Check How Much It Costs?
Bharat Biotech announces price of nasal vaccine - Check How Much It Costs?
Dec 27, 2022
zeebiz.com
Covaxin manufacturer Bharat Biotech to carry out clinical trials in US
Covaxin manufacturer Bharat Biotech to carry out clinical trials in US
Jun 12, 2021
INDIA TV
Bharat Biotech starts phase III trials for Covaxin
4:22
Bharat Biotech starts phase III trials for Covaxin
Nov 17, 2020
timesnownews.com
3:33
Bharat Biotech gets nod to run trials for nasal COVID vaccine as booster dose - CNBC TV18
Jan 4, 2022
cnbctv18.com
2:55
Joining the race for a COVID vaccine, Bharat Biotech has said that they have aimed the rollout of Covaxin by mid-2021, pending approval. | News18
1.2K viewsNov 22, 2020
FacebookNews18
Covid-19 vaccine: Expert panel seeks clarifications from Bharat Biotech ahead of 'Covaxin' phase-3 trials
Oct 10, 2020
India TodayIndia Today Web Desk
Covaxin vaccine to be available in first quarter of next year: Bharat Biotech
Dec 9, 2020
oneindia.com
Covaxin gets shelf life extension up to 12 months: Bharat Biotech
Nov 3, 2021
INDIA TV
7:04
Hyderabad-based Bharat Biotech is working on developing what could be a nasal vaccine to fight the coronavirus pandemic. This vaccine, when ready, will be delivered intranasally. NDTV's Uma Sudhir spoke with Bharat Biotech Joint Managing Director Suchitra Ella. | NDTV
46.1K viewsApr 28, 2020
FacebookNDTV
Bharat Biotech's Covaxin to get WHO nod this week, say sources
Sep 13, 2021
INDIA TV
2:28
Bharat Biotech announces interim analysis results of Phase3 trials Track latest news updates https://bit.ly/2Qo1kkm | The Economic Times
14.7K viewsApr 21, 2021
FacebookThe Economic Times
After SII, Bharat Biotech reduces Covaxin price; ₹400 per dose for state govts
Apr 29, 2021
Hindustan TimesMohammad Shuaib
1:05
Animal trials of Bharat Biotech vaccine candidate Covaxin successful
Sep 12, 2020
India TodayIndia Today Television
1:03
Bharat Biotech plans to launch its Covid-19 vaccine in Q2 of next year. The release is contingent on whether it gets the requisite approvals from the Indian regulatory authorities. Its immediate focus is to conduct the Phase 3 trials successfully across sites in the country. Covaxin-the company's vaccine candidate- has been developed in collaboration with the ICMR and National Institute of Virology. They used inactivated Sars-Cov-2, the virus that causes Covid-19. The virus was isolated in an IC
24.7K viewsNov 1, 2020
FacebookThe Times of India
1:39
Bharat Biotech completed the final analysis of its vaccine Covaxin as a part of phase III clinical trials. The pharmaceutical claimed that an overall efficacy of 77.8% against symptomatic Covid-19 patients has been found in Covaxin. | DDNewsLive
21.9K viewsJul 3, 2021
FacebookDDNewsLive
2:53
A letter by the ICMR asked the company to launch Covaxin by August 15. Bharat Biotech has been asked to accelerate its trails as well and to adhere to the timelines. even DCGI has cleared 'Covaxin' trails. | News18
10.4K viewsJul 4, 2020
FacebookNews18
Two PSUs enter into pact with Covaxin maker Bharat Biotech to produce Covid vaccines
May 13, 2021
timesnownews.com
7:36
Bharat Biotech has released the final phase 3 efficacy data. The company claims it's made in India vaccine, Covaxin, has shown overall efficacy of 77.8%. The data, however, is yet to be peer-reviewed. | NDTV
9.4K viewsJul 3, 2021
FacebookNDTV
10:26
Bharat Biotech Releases Covaxin's Phase 3 Trial Data, Claims 77.8% Efficacy
Jul 3, 2021
NDTV
Bharat Biotech's Covid Nasal Vaccine Gets Regulator's Nod For Holding Phase 2, 3 Clinical Trials
Aug 13, 2021
abplive.com
Covaxin shows 77.8% efficacy in phase 3 trial, likely to get clearance today
Jun 22, 2021
INDIA TV
Bharat Biotech Ties Up With Ocugen For Sale, Manufacture of Covaxin in Canada
Jun 3, 2021
india.com
Bharat Biotech ramps up Covaxin production, to now manufacture 1 billion doses per year
May 20, 2021
INDIA TV
Inactivated vaccines safest with lesser adverse reactions: Bharat Biotech
Dec 21, 2020
INDIA TV
COVID-19 vaccine: Bharat BioTech and Ocugen team up to develop Covaxin for US market
Dec 22, 2020
india.com
See more
Static thumbnail place holder